TSC1/2 gene detection and Everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-16008236

Enrollment

Unknown

Registered

2016-04-07

Start date

2016-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal angiomyolipoma

Interventions

10mg Everolimus:Everolimus 10mg QD for three months

5mg Everolimus:Everolimus 5mg QD for six months

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed of renal angiomyolipoma (more than two measurable lesions,the diameter more than 4cm in more than one lesion); 2. Male or female and 18 years of age or older; 3. Signed a informed consent; 4. Cooperate the follow-up; 5. No partial nephrectomy or renal surgery indications; 6. Good cardiopulmonary function.

Exclusion criteria

Exclusion criteria: 1. Serious illness (e.g., cardio-cerebrovascular disease, unable to cooperate to complete related inspection); 2. Mental disorder or not cooperation; 3. Malignant lesions cannot be excluded by imaging examination; 4. Can't cooperate with the visitor; 5. Tumor rupture hemorrhage appeared in the past six months. 6. Moderately severe anemia, or lung infection.

Design outcomes

Primary

Measure	Time frame
the rate of best ratio relieve patients;	—

Secondary

Measure	Time frame
Objective response rate;Disease control rates;Disease progression-free time;	—

Countries

China

Contacts

Public ContactGuo Gang

greenguo@sina.com+86 10-66875509

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026